Bringing a new therapy to patients depends on more than scientific innovation. It depends on identifying, enrolling, and retaining the right participants within planned timelines. Yet patient recruitment remains one of the most significant operational challenges in clinical development, affecting timelines, development costs, and the speed at which new therapies reach patients.
Having supported more than 300 Phase II to IV clinical trials across diverse therapeutic areas, Lambda Therapeutic Research and Novum Pharmaceutical Research Services have encountered recruitment challenges in many forms: an overestimated patient population, a protocol that works well on paper but proves difficult to implement in practice, or a high-performing site competing for the same participants as several other studies.
Over the years, we’ve learned that recruitment is rarely limited by the number of eligible patients. More often, success depends on realistic feasibility, selecting the right sites, engaging investigators early, and maintaining operational focus throughout the study.
Recruitment Challenges Often Begin Before Site Initiation
Many recruitment challenges originate long before the first patient is screened.
Disease prevalence alone does not determine whether recruitment targets will be achieved. Investigator availability, competing studies, referral pathways, institutional review timelines, and local healthcare practices all influence how quickly eligible participants can be identified and enrolled.
For this reason, feasibility is far more than a site identification exercise. It requires evaluating historical site performance, therapeutic expertise, patient availability, competing studies, and regional operational considerations to develop recruitment forecasts grounded in real-world execution.
When feasibility is approached strategically, sponsors can reduce recruitment uncertainty before study start-up and establish a stronger foundation for study execution.
The Right Sites Are More Valuable Than More Sites
Adding sites after recruitment slows rarely restores lost momentum. Selecting the right sites from the beginning has a far greater impact on enrollment performance.
High-performing sites are not necessarily the largest or most recognized institutions. Recruitment success is often driven by experienced investigators, dedicated study coordinators, established referral networks, access to eligible patients, and the site’s ability to prioritize the study alongside other research commitments.
In multinational clinical trials, these considerations become even more important. Site performance varies across countries due to differences in healthcare infrastructure, patient pathways, and regulatory processes. Balancing local expertise with centralized study oversight helps maintain consistent recruitment across participating regions.
Recruitment Strategies Must Reflect the Therapeutic Area
No two clinical trials face the same recruitment challenges. The operational considerations for a neonatal ophthalmology study are very different from those for oncology, dermatology, psychiatry, or pediatric research.
One example is Phase IV study evaluating ranibizumab for Retinopathy of Prematurity (ROP). The study required recruitment of 50 preterm infants across six sites within just 2.5 months. Through detailed feasibility assessments, selection of hospitals with established neonatal intensive care units (NICUs), and close collaboration between ophthalmologists and neonatologists, the recruitment target was achieved within the planned timeline.
Recruitment at scale presents a different challenge. In a global multicenter clinical trial evaluating a Denosumab biosimilar, Lambda coordinated patient enrollment across countries and investigator sites while maintaining consistent study execution and regulatory compliance. The study demonstrated the importance of centralized project management, investigator engagement, and cross-regional operational coordination in maintaining consistent execution across a large multinational trial.
A different approach was required for a multicenter clinical trial evaluating Topical Tacrolimus for Atopic Dermatitis, where coordinated site activation, sustained investigator engagement, and centralized operational oversight helped maintain enrollment across participating centers while ensuring protocol compliance.
Oncology studies present another layer of complexity. During a multicenter clinical trial evaluating Doxorubicin, close collaboration with investigators, proactive site management, and continuous monitoring of recruitment performance helped sustain enrollment despite stringent eligibility criteria and a highly competitive research environment.
Studies involving pediatric populations demand equally specialized planning. A multicenter acceptability study of Cyclophosphamide Powder required close coordination with pediatric oncology centers and treating physicians to identify eligible participants while maintaining rigorous ethical and safety standards.
Similarly, a pediatric clinical trial evaluating Pegfilgrastim for Rhabdomyosarcoma & Wilms’ Tumor highlighted the importance of investigator engagement and patient-focused operational planning when recruiting younger participants.
Operational resilience also becomes critical when external circumstances disrupt clinical research. During a patient-based pharmacokinetic study of Paliperidone in patients with schizophrenia, conducted during the COVID-19 pandemic, Lambda adapted study operations to maintain participant continuity, protect study integrity, and preserve data quality despite unprecedented logistical challenges.
Each of these studies required a different operational approach, reinforcing that recruitment strategies must be aligned with the therapeutic area, patient population, and practical realities of clinical care.
Recruitment Success Extends Beyond Enrollment
Enrolling participants is only one milestone. Retaining them through study completion is equally important for maintaining statistical integrity, minimizing protocol deviations, and ensuring reliable clinical data.
Early withdrawal, missed visits, and protocol deviations can have a significant impact on study quality. Proactive retention planning helps reduce these risks while preserving data completeness and study integrity.
Effective participant retention depends on experienced site teams, clear communication, proactive issue resolution, and consistent engagement throughout the study. These activities are closely linked with project management, medical monitoring, data management, and site oversight, making recruitment and retention integral components of overall clinical operations rather than standalone functions.
Experience Makes the Difference
Successful patient recruitment is inseparable from overall clinical trial execution. Every operational decision, from feasibility and country selection to site activation and participant retention, influences whether a study remains on schedule.
With experience spanning more than 300 Phase II to IV clinical trials and over 90,000 patients enrolled, Lambda Therapeutic Research & Novum Pharmaceutical Research Services supports sponsors with integrated late-phase clinical development services that combine feasibility assessments, site management, patient recruitment and retention, medical monitoring, biometrics, regulatory support, and centralized project oversight.
Successful patient recruitment is built on experience, planning, and operational execution. It requires informed feasibility assessments, the right investigator network, strong site engagement, and continuous oversight throughout the study.
For sponsors conducting regional and multinational clinical trials, these capabilities help maintain study momentum while supporting the quality, compliance, and scientific rigor expected throughout clinical development.
Ready to Advance Your Clinical Trial?
Whether you’re planning a regional or multinational clinical trial, our team can help assess feasibility, identify high-performing sites, and support patient recruitment through study completion. Speak with our experts to explore the right approach for your next study.
